Stay updated with breaking news from Disability Index. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Switching from biosimilar CT-P13 to SB2 is safe and effective, according to new research. The patients in the study had no significant changes in their psychometric assessments during the 12 month follow up.
A network meta-analysis lends "compelling" support to the practice of switching patients with RA from biologics to less costly biosimilars at 6 months.
A switch from a biologic treatment to a biosimilar demonstrated comparable effects for both primary and co-primary outcomes in patients with rheumatoid arthritis.
August's Condition Watch focuses on skin health.
-- New data illustrate impact of KRYSTEXXA (pegloticase) injection with methotrexate to improve patient outcomes and clinical measures for uncontrolled gout -- Horizon Therapeutics plc (Nasdaq: HZNP)